Effect of race on cardiometabolic responses to once-weekly exenatide: insights from the exenatide study of cardiovascular event lowering (exscel)

HIGHLIGHTS

• who: Timothy M. E. Davis from the diseaseThe trial was run jointly by the Duke Clinical Research Institute and the University of Oxford Diabetes Trials Unit in an academically independent collaboration with the sponsor, Amylin Pharmaceuticals (a wholly owned subsidiary of AstraZeneca) [11]. Participants could be enrolled if treated with a maximum of three oral blood glucose-lowering drugs, or insulin alone or in combination with up to two oral blood glucose-lowering drugs [12]. As part of baseline assessment, participants were asked to self-identify their racial background as Indian (American) or Alaska Native, Asian, Black . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.